Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (01) : 53-57     DOI: 10.3971/j.issn.1000-8578.2022.21.0794
|
Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification
CHEN Long1, LIU Yujie1, TIAN Suqing2, WANG Cuiying1, HE Donglei3
1. Department of Oncology, Sanya Central Hospital, The Third People’s Hospital of Hainan Province, Sanya 572000, China; 2. Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China; 3. Department of Gastrointestinal Cancer Surgery, The First Affiliated Hospital of Hainan Medical College, Haikou 570100, China
Download: PDF(3022 KB)   ( 34 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification. Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients<60 kg. The locoregional therapy group only received locoregional therapy. We retrospectively analyzed the clinical data and prognosis of two groups. Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group, respectively (P<0.05). The response rate, disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P<0.05). Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification.
Keywords Hepatocellular carcinoma; Lenvatinib; Locoregional therapy; Portal vein tumor thrombus; PD-L1     
ZTFLH:  R735.7  
Issue Date: 11 January 2022
 Cite this article:   
CHEN Long,LIU Yujie,TIAN Suqing, et al. Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 53-57.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0794
http://www.zlfzyj.com/EN/Y2022/V49/I01/53
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
CHEN Long
LIU Yujie
TIAN Suqing
WANG Cuiying
HE Donglei
[1] Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating
primary hepatocellular carcinoma with portal vein tumor
thrombus[J]. Int J Surg, 2015, 20: 8-16.
[2] Katagiri S, Yamamoto M. Multidisciplinary treatments for
hepatocellular carcinoma with major portal vein tumor
thrombus[J]. Surg Today, 2014, 44(2): 219-226.
[3] 孙非凡, 李栋, 李华, 等. 程序性死亡配体1在索拉非尼耐药
肝癌细胞中的表达及功能[J]. 第二军医大学学报, 2018,
39(2): 152-158. [Sun FF, Li D, Li H, et al. Expression and
role of programmed cell death ligand-1 in sorafenib-resistant
hepatocellular carcinoma cells[J]. Di Er Jun Yi Da Xue Xue Bao,
2018, 39(2): 152-158.]
[4] 广东省抗癌协会肝癌专业委员会, 广东省医学会肝胆胰外科
学分会.肝细胞肝癌合并门静脉癌栓多学科团队综合治疗
广东专家共识(2015版)[J]. 中华消化外科杂志, 2015, 14(9):
694-701. [The Society of Liver Cancer of Guangdong Anti-cancer
Association,The Society of Hepato-Pancreato-Biliary Surgery of
Guangdong Medical Association. Cantonese expert consensus
on multidisciplinary team treatment for hepatocellular carcinoma
with portal vein tumor thrombus(2015 edition)[J]. Zhonghua Xiao
Hua Wai Ke Za Zhi, 14(9): 694-701.]
[5] National Comprehensive Cancer Network. NCCN clinical practice
guidelines in oncology (NCCN guidelines) Hepatocellular
Carcinoma(version 5.2020)[EB/OL]. https://www.nccn.org/
professionals/physician-gls/pdf/hepatobiliary-pdf.
[6] Llovet JM, Ricci S, Mazzaferm V, et al. Sorafenib in advanced
hepatocellular carcinoma[J]. N End J Med, 2008, 359(4): 378-390.
[7] Cheng AL, Kang YK, Chen Z, et al. Emcacy and safety of sorafenib
in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase Ⅲ randomized, double-blind placebocontrolled
trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[8] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in
first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomized phase 3 non-inferiority trial[J]. Lancet,
2018, 391(10126): 1163-1173.
[9] 黄海, 竺越, 保志军, 等. 肝动脉化疗栓塞术治疗老年肝癌病人
的疗效及预后影响因素分析[J]. 实用老年医学, 2019, 33(6):
577-581. [Huang H, Zhu Y, Bao ZJ, et al. Prognostic factors
of elderly patients with hepatocellular carcinoma undergoing
transcatheter arterial chemoembolization[J]. Shi Yong Lao Nian
Yi Xue, 2019, 33(6): 577-581.]
[10] 王洪云. 甲磺酸仑伐替尼联合TACE治疗中晚期原发性肝癌
的临床效果及安全性分析[J], 中国医学创新, 2020, 17(31):
6-9. [Wang HY. Analysis on the Clinical Effect and Safety of
Lenvatinib Mesilate Combined with TACE in the Treatment of
Patients with Metaphase and Advanced Primary Liver Cancer[J].
Zhongguo Yi Xue Chuang Xin, 2020, 17(31): 6-9.]
[11] 余紫珊, 何敏柯, 张耀军, 等. TAI 联合索拉非尼和单用索拉非
尼对伴门脉 主干或主分支癌栓的肝癌的疗效比较[J]. 广东医
学, 2018, 39(8): 1213-1222. [Yu ZS, He MK Y, Zhang YJ, et al.
Sorafenib combined with transcatheter arterial infusion versus
sorafenib alone for hepatocellular carcinoma with major portal
vein carcinoma thrombosis[J]. Guangdong Yi Xue, 2018, 39(8):
1213-1222.]
[12] Tsuchiya K, Kurosaki M, Kaneko S, et al. A nationwide multicenter
study in patients with unresectable hepatocellular carcinoma
treated with lenvatinib in real world practice in Japan[J]. J Clin
Oncol, 2019, 37(4-supl): 364.
[13] 袁冰, 王燕, 张金龙, 等. 仑伐替尼治疗经肝动脉化疗栓塞术
无效的中晚期肝细胞癌患者的临床观察[ J ] , 中华医学杂
志, 2020, 100(11): 833-836. [Yuan B, Wang Y, Zhang JL, et al.
Value of lenvatinib for the treatment of advanced hepatocellular
carcinoma[J]. Zhonghua Yi Xue Za Zhi, 2020, 100(11): 833-836.]
[14] 郅新, 高健, 郑晟旻, 等. 肝细胞癌经动脉化疗栓塞治疗的应用
现状与研究进展[J]. 中华普通外科杂志, 2019, 34(8): 742-744.
[Zhi X, Gao J, Zheng S, et al. Research progress of transcatheter
arterial chemoembolization treatment of hepatocellular
carcinoma[J]. Zhonghua Pu Tong Wai Ke Za Zhi, 2019, 34(8):
742-744.]
[15] 王慧, 顾红燕, 彭德明, 等. 仑伐替尼致不良反应文献分析[J]. 中
国新药杂志, 2020, 29(14): 1675-1680. [Wang H, Gu HY, Peng
DM, et al. Literature analysis of adverse drug reactions induced
by lenvatinib[J]. Zhongguo Xin Yao Za Zhi, 2020, 29(14):
1675-1680.]
Related articles from Frontiers Journals
[1] WANG Zhihui, ZHANG Shuijun. Influence of Multidisciplinary Combined Therapy on Curative Effect of Liver Cancer Treatment[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 880-885.
[2] ZHANG Wenjing, ZHANG Gufen, WANG Xiaoyan, ZHANG Ying, QUAN Huiqin. Mechanism of HBx Protein Inhibiting DKK4 Expression and Its Effect on Proliferation and Migration of Hepatocarcinoma Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 899-903.
[3] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[4] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[5] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[6] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[7] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[8] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[9] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[10] CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 438-443.
[11] ZHOU Hong, ZHANG Haibo, YAN Ruijuan, WEI Hailiang, YAN Shuguang, LI Jingtao, CHANG Zhanjie. Mechanism and Role of circRNA in Occurrence and Development of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 496-502.
[12] ZHOU Yongjie, WANG Zhengfeng, YAN Jun, WANG Haiping, XU Wen, ZHOU Wence. Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 347-351.
[13] TAO Changcheng, ZHANG Kai, RONG Weiqi, WU Jianxiong. Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 359-363.
[14] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[15] PANG Kangqing, MA Hongde, YANG Rulei, PANG Guohong. Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1078-1081.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed